Key facts
- Inductive Bio’s last known valuation is $80.0M (May 2025).
- It has raised $29.4M across 2 recorded rounds; the latest was Early Stage VC ($25.1M) in Mar 2025.
- Notable investors include Andreessen Horowitz, Bessemer Venture Partners, Lux Capital, AlleyCorp, S32 — 16 tracked in total.
- Inductive Bio has filed 1 Form D with the SEC, most recently May 2025 ($25.1M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Inductive Bio
Funding rounds
2 roundsAbout Inductive Bio
Developer of a machine learning platform designed to accelerate the compound optimization process. The company's platform specializes in building datasets and machine learning (ML) models to map the drivers of small molecule absorption, distribution, metabolism, excretion, and toxicity (ADMET), enabling scientists to optimize initial compounds into leads and development candidates faster and with a better balance of properties which helps them develop new therapeutics.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Website
- inductive.bio/
- Ownership
- Privately Held (backing)
Inductive Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inductive Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inductive Bio in its N-PORT filings yet. We sweep new filings monthly.